USA Delivery yasekhaya, i-Canada Domestic Delivery, i-European Domestic Delivery

I-Alprostadil, (PGE1), i-Prostaglandin E1

Isilinganiselwa:
5.00 koku 5 ngokusekelwe ku 1 isilinganiso ikhasimende
SKU: 745-65-3. Isigaba:

I-AASraw inekhono lokuqamba nokukhiqiza kusuka kugramu ukuya ku-Alprostadil, (PGE1), i-Prostaglandin E1 (745-65-3), ngaphansi komthethonqubo we-CGMP kanye nesistimu yokulawula ikhwalithi.

I-Prostaglandin E1 (PGE1), eyaziwa nangokuthi i-alprostadil, i-prostaglandin eyenziwa ngokwemvelo esetshenziselwa imithi. Ezinganeni ezineziphambeko zenhliziyo ezizalwayo, isetshenziswa ukujola kancane kancane emvuthweni wokuvula i-ductus arteriosus kuze kufike ukuhlinzwa. Ngomjovo wangena epeniseni noma ukubekwa ku-urethra, isetshenziselwa ukuphatha ukungasebenzi kahle kwe-erectile.

I-AASRAW powder PDF Icon

Product Incazelo

I-Alprostadil, (PGE1), ividiyo ye-Prostaglandin E1


I-Alprostadil, (PGE1), i-Prostaglandin E1 Characters eyisisekelo

Igama: I-Alprostadil, (PGE1), i-Prostaglandin E1
CAS: 745-65-3
Formula Yamamolekhula: C20H34O5
Isisindo somzimba: 354.48
I-Melt Point: I-115-116 ° C
Isitoreji Sokugcina: I-2 ° -8 ° C
Umbala: powder emhlophe


I-Alprostadil, (PGE1), ukusetshenziswa kwe-Prostaglandin E1 (745-65-3) kumjikelezo we-steroids

Amagama

I-Alprostadil, (PGE1), i-Prostaglandin E1 (i-CAS 745-65-3), ebizwa nangokuthi i-Avastin ne-Mvasi.

I-Alprostadil, (PGE1), i-Prostaglandin ukusetshenziswa kwe-E1

I-Bevacizumab iza njengesisombululo sokuphatha kancane kancane emthanjeni. I-Bevacizumab ilawulwa udokotela noma umhlengikazi ehhovisi lezokwelapha, isikhungo sokungeniswa, noma esibhedlela. I-Bevacizumab ivame ukunikezwa kanye kanye namaviki onke e-2 noma e-3.

Kufanele kuthathe imizuzu ye-90 ukuze uthole umthamo wakho wokuqala we-bevacizumab. Udokotela noma unesi uyokubuka eduze ukuze ubone ukuthi umzimba wakho uphendukela kanjani ku-bevacizumab. Uma ungenayo izinkinga ezinkulu lapho uthola umthamo wakho wokuqala we-bevacizumab, ngokuvamile uzothatha i-30 kumaminithi we-60 ukuze uthole imithi yakho ngayinye ekhona yomuthi.

Umjovo we-Bevacizumab ungabangela ukusabela okujulile ngesikhathi kukhishwa imithi. Uma uthola noma iyiphi yalezi zimpawu ezilandelayo, tshela udokotela wakho ngokushesha: ukuphefumula ukuphefumula noma ukuphefumula, ukugubha, ukuthuthumela, ukujuluka, ikhanda, isifuba, isizungu, ukuzwa ukuphelelwa amandla, ukuhlwitha, ukuchithwa, ukuqhuma noma ukuvuthwa. Udokotela wakho angase adinge ukunciphisa ukumnika kwakho, noma ukubambezela noma ukumisa ukwelashwa kwakho uma uhlangabezana nalezi noma eminye imiphumela emibi.

Indlela u-Alprostadil, (PGE1), i-Prostaglandin E1 (745-65-3) esebenza ngayo

Ukuze ukwelashwa kwe-erectile i-dysfunction (ED), i-alprostadil ibuyisela emuva imisipha ebushelelezi ye-corpus cavernosum; Kodwa-ke, indlela eqondile yokusebenza ayifakazi. Kubonakala sengathi imiphumela yenzelwa ukwandisa izingxube ze-intracellular ze-AMP ye-cyclic. U-Alprostadil uxhumane nama-receptors ethize ahambelane ne-membrane avuselela i-adenylate cyclase futhi aphakamise i-AMP ye-intracellular cyclic, okuholela ekusebenziseni amaprotheni kinase kanye nokuphumula kwemisipha ehamba phambili. Lesi senzo sihluke ne-papaverine esivimbela i-phosphorylation ye-phosphorylation eyenziwe nge-oxidative in-activation ye-AMP ye-cyclic futhi iphazamise ukugqugquzela i-calcium ngesikhathi sokuqhaqhazeka kwemisipha. I-Alprostadil ingase iphinde ihlukumeze izinyathelo ze-vasoconstrictive ze-norepinephrin ngokuvimbela ukukhululwa kwe-neuronal ye-norepinephrin futhi kungathuthukisa izenzo ze-nonurogenergic neurotransmitter non-nonerglinergic. Lapho ukwelapha i-ED, i-alprostadil iveza ukulungiswa ngokuziphumuza imisipha ebushelelekile futhi ivuselele imishanguzo ye-cavernosal namagatsha awo. Ukuhlukunyezwa kwemithambo ye-Cavernosal kuhambisane nokukhula kwe-inflation okuqhubekayo nokunyuka kwe-venous outflow resistance. Ngenxa yalokho, izikhala ze-lacunar zanda futhi igazi liba yingxenye yesibili yokucindezelwa kwama-venules ngokumelene ne-tunica albuginea. Ukuze kutholakale i-tumescence ne-rigidity eyanele, i-tunica albuginea kufanele ibe nzima ngokwanele ukucindezela ama-vené engena ngaphakathi futhi ngaleyo ndlela ivimbele ukuphuma kwe-venous. Le nqubo iphinde ibhekiswe njengendlela ye-veno-occlusive ye-corporal. I-Alprostadil ayithinti ngqo i-ejaculation noma i-orgasm.

Lapho ukwelashwa kwe-ductus arteriosus-encike ekutheni izinhliziyo zenhliziyo ezifayo, i-alprostadil igcina i-ductal patency ngokuphumula imisipha ebushelelezi ye-ductus arteriosus. I-Alprostadil isebenza kuphela uma ihlinzekwa ngaphambi kokuvalwa okuphelele kwe-anatomic ye-ductus arteriosus. Ukulawulwa kwe-alprostadil ye-neonates ne-cyanotic yokukhubazeka kwenhliziyo (okuvinjelwe ukuphuma kwegazi kwe-pulmonary) kuholela ekukhuleni kwegazi legazi kanye / noma ukwanda kokuxubana phakathi kwe-systemic kanye ne-pulmonary circulation okuholela ekunyuseni okwesikhashana kokucindezela okwenyuka kwe-oxygen (PaO2) ne-oxygen saturation. Ukusabela kwe-cyanotic neonate kuya kwe-alprostadil therapy nayo ihlobene nokuxoshwa kwe-PO2. Impendulo enkulu kunazo zonke ibonakala kulawo ma-neonates ane-low pretreatment PaO2 (<20 torr), ama-ductus arteriosus anciphisa, futhi yiziphi izinsuku ezingu-4 ezindala noma ezincane. I-Neonates nama-PaO2 amanani we-40 torr noma ngaphezulu ayinayo impendulo encane ku-alprostadil.

Ezingxenyeni ezihambisana nokugeleza kwegazi okungavinjelwe, ukuphathwa kwe-alprostadil kungabangela ukuvimbela noma ukulungiswa kwe-asiememia, ukukhuphuka komzimba okwenyuka ngokweqile nokunyuka kwengcindezi yegazi, ukukhuphuka komthamo wegazi wesifazane, ukwandisa ukugeleza kwegazi le-renal kanye nokusebenza, ukwehla kwezinga eliphansi lokunciphisa ukunyuka kwe-aortic yegazi (ku-neonates ne-coarctation ye-aorta), kanye / noma ukunciphisa isilinganiso somfutho we-arthmone ukucindezela kwe-aortic (ku-neonates nokuphazanyiswa kwe-arch aortic). Ngokungafani nama-cyontic neonates, ukusebenza kahle kwe-alprostadil kuma-aconanotic neonates akuxhomeki ekudala noma kokudlulela kwe-PaO2.

Imiyalo eyengeziwe

I-Alprostadil (i-Prostglandin E1) isetshenziselwa ukwelapha ukukhubazeka kwe-erectile (ED) kumadoda amadala. Ukusebenza kwe-alprostadil ekwelapheni i-ED kuyahluka nalokho okubangela; izinga lokuphendula ngokuvamile liphansi ezigulini ezine-ED ngenxa yezinhlobo ezixubekile eziqhathaniswa nalabo abane-ED ngenxa yezinzwa ze-neurogenic, ze-psychogenic, noma ze-vasculogenic. Amafomu amabili e-dosage athengiswa ukuphatha i-ED: umkhiqizo we-transurethral (Muse) osebenzisa i-pellet ehlotshisiwe ephethwe i-urethra nomjovo (Caverject noma i-Edex) ejoqwe ngqo kwi-corpus cavernosa. Amanye amafomu wokulinganisa afana nejelisi ye-topical kanye ne-non-invasive liposomal system delivery delivery ngaphansi kokuphenywa. Ngokomhlahlandlela wezokwelapha we-ED, uhlobo lwe-phosphodiesterase yomlomo lwe-5 inhibitors (i-PDE5 inhibitor) lubhekwa ukwelashwa kwelayini lokuqala. Izinketho zokuthola ukwelashwa kwamabili zibandakanya umjovo we-intracavernous kanye ne-intra-urethral therapy. Ukwelashwa kwe-Intracavernous injection iyindlela yokwelashwa engapheli kakhulu ye-ED, ngokuphendula okubikezelayo nokuqhubekayo. Kodwa-ke, kuyinhlekelele futhi iyaphazamisa imiphumela emibi efaka hlangana ukungaziphathi kahle kanye ne-penile fibrosis. Ukugunyazwa kwe-FDA kulandelayo: I-Caverject ngoJulayi 1995, i-MUSE ngo-Okthoba 1996, no-Edex ngoJuni 1997.

I-Alprostadil namanye ama-prostaglandin ku-E uchungechunge lwe-E ngokwawo ngokwemvelo ikhona ku-placenta ne-ductus arteriosus ye-fetus. I-type E-prostaglandins vasodilate arterioles ngokuphumula ngokuqondile kwe-muscular smooth muscle. Ezinye imiphumela ye-pharmacologic zifaka ukwanda komkhiqizo we-cardiac, ukuhlanza kokubili imikhumbi yesistimu kanye ne-pulmonary, ukuxoshwa kwe-ductus arteriosus, ukuvinjelwa kwe-platelet aggregation, ukuphumula kwemisipha ye-bronchial, ukwanda kokugeleza kwegazi lomnyoba, nokulibaziseka kwesikhathi sokuchitha isikhathi esiswini. I-alprostadil engathandeki isetshenziselwa ama-neonates nokuvinjelwa kokuphuma kwesokudla noma kwesobunxele be-ventricular ukugcina ubuciko be-ductus arteriosus kuze kufike isikhathi sokuhlinzwa okulungiswa noma okulula. Ngokuvamile i-Alprostadil isebenza kahle kulawo ma-neonates ane-blood pretreatment PO2 futhi yiziphi izinsuku ezingu-4 ezindala noma ngaphansi. Ezingxenyeni ezindala kunezinsuku ezingu-4, kunciphisa ukuguqulwa kwemisipha ehamba phambili ngenxa yezinguquko ezingezansi emva kokubeletha odongeni lwe-ductus arteriosus. I-alprostadil engathandeki idinga ukunakekelwa kokuphefumula phakathi nokuphatha ngenxa yokuthi i-apnea iqala ku-10-12% yezinsaonate. I-Alprostadil i-FDA evunyelwe ezigulini zezingane njengoba zincane njengezingqinamba. I-Prostin VR Isifo sezingane yamukelwa yi-FDA ku-1981.


Indlela yokuthenga i-Alprostadil, (PGE1), i-Prostaglandin E1 kusuka ku-AASraw

1.Ukuxhumana nathi nge-imeyili yethu uhlelo lokuphenya, noma isibhakabhaka se-inthanethiummeleli wenkonzo yamakhasimende (CSR).
I-2.Ukusihlinzekela ngobuningi bakho kanye nekheli lakho elibuziwe.
I-3.I-CSR yethu izokunikeza ikhothethini, isikhathi sokukhokha, inombolo yokulandelela, izindlela zokulethwa kanye nosuku lokufika olulinganisiwe (i-ETA).
I-4.Inkokhelo eyenziwe futhi izimpahla zizothunyelwa kumahora we-12 (Ukuhleleka ngaphakathi kwe-10kg).
Ama-5.Goods athola futhi anikeze imibono.


=

COA

I-HNMR

Ungadliwa

Okubhekiselweyo nokuhlungwa komkhiqizo